- HealthTech
- Tuesday, 09 Jun 2020
WuXi Biologics Signs Lease for a Clinical Manufacturing Facility in the United States
The new clinical manufacturing facility will install total 6000 L bioreactors, Process Development (PD), Quality Control (QC) labs, along with supporting functions. The 66,000-square-foot facility is expected to become operational in late 2020 and will bring in up to 100 jobs to the region.
This news follows WuXi Biologics' recent purchase of land to build a new 107,000-square-foot clinical and commercial manufacturing facility in Worcester, Massachusetts, and the lease of a 33,000-square-foot site to establish a process development lab in King of Prussia, Pennsylvania.
"We are excited to announce our third site in the United States and proud to become a member of the New Jersey community. Cranbury is a growing hub for the biotech and biopharma industries, and we look forward to working with and serving our partners in the area to benefit patients worldwide," said Dr. Chris Chen, CEO of WuXi Biologics.
Related Industry Updates
Europe Bioactive Wound Management Market is expected to reach US$ 676.54 Million by 2027 with CAGR of 7.9% | Hartman Group, Coloplast Group
Feb 05, 2021
Asia Pacific Anti-Viral Therapies Market to See Fabulous Rise during 2019-2027| Business Market Insights
Mar 05, 2021
Brain Biomarkers Market Huge growth by key players Seimens Healthnineers, Brainscope, Ge Healthcare
Apr 12, 2021
Capital Rx Wins Top Award at Accenture HealthTech Innovation Challenge
Feb 11, 2020
Wound Irrigation System Market Share, Size, Trends, Top Players and Forecast by 2026 | BSN Medical, C.R. Bard, Inc, CooperSurgical, Inc, Stryker Corporation, Zimmer Biomet
Mar 10, 2021
Global Preimplantation Genetic Diagnosis Market 2021-2027: Industrial Output, Import & Export, Consumer Consumption and Forecast 2027
Apr 21, 2021
US Occupational Health Market is expected to reach US$ 1,496.92 million by 2028
Mar 22, 2023
Follow us on
